Compare Eli Lilly And Co (LLY) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Roundhill Magnificent Seven ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Roundhill Magnificent Seven ETF trades at $73.73 (market cap $5.78B). The key difference: Eli Lilly And Co is far larger — about 179.9× Roundhill Magnificent Seven ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Roundhill Magnificent Seven ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Roundhill Magnificent Seven ETF for 36 Days on average.
| LLY | MAGS | |
|---|---|---|
Market Cap | $1.04T | $5.78B |
Volume | 3,064,878 | 4,410,665 |
Sector | Health | Sector/Thematic |
52-Week High | $1.28K | $73.90 |
52-Week Low | $799.57 | $55.39 |
Typical Hold Time | 93 Days | 36 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
MAGS (Roundhill Magnificent Seven ETF) trades at $73.03, down 0.9% on the day but maintains a bullish technical outlook with strong moving average signals. The ETF provides equal-weighted exposure to seven mega-cap tech leaders, though it has underperformed the broader market in 2026 with only 2% year-to-date gains. Recent news highlights the ongoing debate about the Magnificent Seven's leadership role as AI spending shifts focus toward semiconductor companies.
The ETF faces near-term pressure from reduced tech dividends and buybacks, but long-term AI exposure remains compelling. Key risks include concentration in seven stocks and market rotation away from mega-caps. Technical support at $71-72 provides a cushion, while resistance at $74-75 represents the next challenge for bullish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
